PRA Health Sciences Inc. (PRAH) Sets New 1-Year High at $52.72
PRA Health Sciences Inc. (NASDAQ:PRAH) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $52.72 and last traded at $52.59, with a volume of 907,815 shares changing hands. The stock had previously closed at $51.75.
A number of research analysts have recently issued reports on PRAH shares. Credit Suisse Group AG started coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They set a “neutral” rating and a $43.00 price objective for the company. KeyCorp reiterated a “hold” rating on shares of PRA Health Sciences in a report on Sunday, May 22nd. Jefferies Group reiterated a “buy” rating and set a $57.00 price objective on shares of PRA Health Sciences in a report on Friday, July 29th. Zacks Investment Research cut shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. Finally, First Analysis started coverage on shares of PRA Health Sciences in a report on Monday, June 20th. They set an “equal weight” rating and a $47.00 price objective for the company. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. PRA Health Sciences currently has a consensus rating of “Hold” and a consensus price target of $48.94.
The company has a market cap of $3.20 billion and a price-to-earnings ratio of 45.10. The company has a 50 day moving average of $46.45 and a 200 day moving average of $44.85.
PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings data on Thursday, July 28th. The company reported $0.63 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.59 by $0.04. The company earned $394.20 million during the quarter, compared to the consensus estimate of $381.25 million. During the same quarter last year, the company posted $0.47 earnings per share. The firm’s revenue for the quarter was up 16.0% compared to the same quarter last year. On average, equities research analysts forecast that PRA Health Sciences Inc. will post $2.46 EPS for the current year.
In other PRA Health Sciences news, VP David W. Dockhorn sold 107,257 shares of the company’s stock in a transaction on Friday, August 12th. The shares were sold at an average price of $49.00, for a total value of $5,255,593.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Colin Shannon sold 113,133 shares of the company’s stock in a transaction on Monday, August 22nd. The stock was sold at an average price of $51.57, for a total transaction of $5,834,268.81. Following the completion of the transaction, the chief executive officer now owns 120,000 shares of the company’s stock, valued at $6,188,400. The disclosure for this sale can be found here.
An institutional investor recently raised its position in PRA Health Sciences stock. Bank of Montreal Can increased its stake in PRA Health Sciences Inc. (NASDAQ:PRAH) by 12.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 231,826 shares of the company’s stock after buying an additional 25,738 shares during the period. Bank of Montreal Can owned approximately 0.38% of PRA Health Sciences worth $10,495,000 at the end of the most recent quarter.
PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.